Aseptic Processing: A Primer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Aseptic Processing: A Primer
PharmTech speaks to Ray O'Connor from the National Institute for Bioprocessing Research and Training (NIBRT) for an overview of aseptic processing.

Pharmaceutical Technology Europe


Ray O'Connor, Operations Consultant, at the National Institute for Bioprocessing Research and Training (NIBRT) discusses the basics of biopharmaceutical facility design and operation. NIBRT provides training, educational and research solutions for the international bioprocessing industry in state-of-the-art facilities. Located in South Dublin (Ireland), it is based on an innovative collaboration between University College Dublin, Trinity College Dublin, Dublin City University and the Institute of Technology Sligo.

Q PTE: Why is aseptic processing crucial for injectables, such as vaccines and other biologic-based products?


iStockphoto/Thinkstock Images
O'Connor: Certain pharmaceutical products must be sterile as they're introduced to the patient by injection because this mode of drug delivery bypasses the body's natural defences. Therefore, with biologics, there is an increased risk of infection being introduced to the patient. Sterile drug products can be manufactured using two techniques: terminal sterilisation or true aseptic processing. Terminal sterilisation usually involves heat or irradiation; however, quite a large proportion of vaccines and biological-based drugs can be destroyed by exposure to heat or irradiation; hence, the requirement to manufacture in an aseptic manner.

According to the FDA's guidance for industry on sterilised drug products produced by aseptic processing issued in September 2004, in an aseptic process, the drug product and container–closure are subjected to sterilisation methods separately, as appropriate, and then brought together. Because there is no process to sterilise the product in its final container, it is crucial the containers be filled and sealed in an extremely high-quality environment. Therefore, aseptic processing involves more variables than just terminal sterilisation. Before aseptic assembly into a final product, the individual parts of the final product must be subjected to various sterilisation processes.

Similarly, in the EU, GMP guidelines state that the manufacture of sterile products is subject to special requirements to minimise the risk of microbial contamination and of particulate and pyrogen contaminant. So, as a result, much of the aseptic process depends on the scale of training and attitudes of the people involved.

It's particularly important that this type of manufacture strictly follow established and validated methods of preparation and procedure. Sole reliance for sterility or other quality aspects would not be placed on any terminal process or finished product testing. To summarise, aseptic processing is minimising the risk of introducing any microbial contaminant into your product as you move it through the manufacturing process.

Q PTE: Aseptic processing and the term 'fill–finish' are often used interchangeably throughout the industry. Are these two terms truly the same or are there unique steps for each?

O'Connor: Fill–finish is a discrete part of the manufacturing process. If you have an upstream or downstream process, that will be where you manufacture your active ingredient. Fill–finish is the filling and packaging part of this process. It comes after the product has been manufactured and is ready to be put into its final package container that the patient will see.

Aseptic processing refers to the various techniques that go into ensuring that the product is free of contaminants, thereby reducing the risk of infection to the patient. Aseptic processing is the processing of drug components, drug product containers and excipients in a manner that precludes microbial contamination of the final sealed product.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
24%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
10%
All of the above.
44%
No government involvement in patient treatment or drug development.
10%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here